Open study to investigate if the eradication rate of H. pylori in adults is improved by L. reuteri DSM 17938, as an adjunct during 10-day eradication therapy and for 10 days thereafter. Forty-five (45) patients were included.

The rate of eradication was 93.3% (42/45). In 2/4 (50%) previously treated for H. pylori the infection was also eradicated.

Side effects were reported in 8 subjects: mild diarrhoea for a few days (n=5), and abdominal discomfort (n=3).

Conclusion: Proton pump inhibitor-tetracycline-metronidazole-L. reuteri therapy provided high eradication rates with few side effects, and excellent compliance.

 

Reference

Dore MP, Soro S, Rocchi C, Loria MF, Bibbò S, Pes GM. Inclusion of Lactobacillus reuteri in the treatment of Helicobacter pylori in Sardinian patients: a case report series. Medicine (Baltimore). 2016;95(15):e3411.

Crawling baby

For the avoidance of doubt, BioGaia’s products are food supplements, and the information on this part of the website should not be interpreted as our products are intended to diagnose, treat, cure or prevent any disease.

The information on this part of the website is intended only for health care and business professionals. If you are not a health care or business professional and would like to learn more about the indications BioGaia works with, please visit our Expertise pages.

Please read terms & conditions before accepting. By clicking on the button “I acknowledge and accept” you confirm that you are a healthcare or business professional and have read and understood this disclaimer including the terms and conditions.